Industry News
Pharmaxis completes capital raising
Pharmaxis (ASX:PXS, Nasdaq:PXSL) has completed its capital raising of AUD$87 million (US$63 million). [ + ]
Canola taskforce finds small contamination
The taskforce appointed by the Australian Oilseeds Federation and the Australian Seeds Federation to investigate the recent detection of genetically modified canola seed in a small, non-GM shipment has found the contamination was limited to just one commercial cultivar. [ + ]
BioMD acquires tissue engineering company
Perth-based medical device and materials company BioMD (ASX:BOD) has paid AUD$650,000 to acquire a 50 per cent equity interest in unlisted tissue engineering company Celxcel. [ + ]
ICT Research Groups develop a research collaboration
Australia's leading ICT research groups have announced the formation of a collaboration to develop advanced information-sharing technology.
[ + ]Glygen appoints ProteoMass
Glygen Corp, specialist in life science sample preparation and delivery tools, has appointed ProteoMass Australia as its exclusive distributor for Australia.
[ + ]Xenome builds team, strengthens US ties
Unlisted Brisbane biotech Xenome is making a strong push into San Diego, hub of the US West Coast biotech industry, in pursuit of venture capital and big pharma partners to develop its long and diverse pipeline of conotoxin peptides from the venom of Australian cone shells. [ + ]
Keith Williams retires as Proteome director, remains as consultant
Proteome Systems (ASX:PXL) founder Dr Keith Williams is no longer a director of the company he established in 1999, following his decision to withdraw his nomination for re-election at yesterday's AGM. [ + ]
French order for Relenza triples cumulative global sales
A French government announcement that it would increase its pandemic stockpile of Relenza from 200,000 units to 9 million units over the next two years has sent shares in Melbourne-based Biota Holding's (ASX:BTA) up by more than 20 per cent. [ + ]
Solbec earns orphan drug status for carcinoma treatment
Solbec Pharmaceuticals (ASX:SBP) has received orphan drug designation from the US Food and Drug Administration for its lead anti-cancer compound Coramsine for the treatment of metastatic renal cell carcinoma (mRCC). [ + ]
Incoming Mayne Pharma CEO sees growth through acquisitions
The incoming chief of Mayne Pharma, the global injectable drugs business soon to emerge from the break-up of Mayne Group (ASX:MAY), said growth would have to come from acquisitions and expansion into new areas. [ + ]
UQ team helps tap into the alcoholic brain
Researchers at the University of Queensland have discovered fundamental differences in patterns of gene expression in alcoholic versus normal brains. [ + ]
Probiomics nets govt grant
Probiomics (ASX:PCC), formerly VRI BioMedical, has received an AusIndustry Commercial Ready grant for the next stage of its molecular discovery program. [ + ]
Ventracor, Heartware settle patent dispute
Artificial heart firms Ventracor (ASX:VCR) and HeartWare (ASX:HTW) have settled a year-long patent dispute. [ + ]
Mimotopes to team with Genzyme in peptide supply deal
PharmAust (ASX:PAA) subsidiary Mimotopes will team up with US-based Genzyme Pharmaceuticals in a strategic alliance to provide peptide products and services to both companies' customers globally. [ + ]
TGR/Nanyang deal
TGR BioSciences has received an equity investment from the Nanyang Innovation Fund managed by Nanyang Ventures (Nanyang). Nanyang will progressively invest up to $3 million into TGR, subject to TGR meeting certain milestones.
[ + ]
